Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells - PubMed (original) (raw)
Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells
S L Friedman et al. Oncogene. 1997.
Abstract
Mutations in the tumor suppressor p53 are a common event in hepatocellular carcinoma (HCC). Because HCCs typically occur in livers with chronic injury and impaired function, we have explored the role of wild-type p53 in regulating the growth and differentiation of Hep 3B hepatoma cells, a p53-negative line derived from a liver cancer. Stable Hep 3B cell lines were generated in which inducible p53 was introduced using either a temperature-sensitive mutant (p53val135) or a tamoxifen-regulated p53-estrogen receptor chimera (p53-mERtm-pBabepuro). In both cell lines, induction of transcriptionally active p53 was confirmed by assessing several p53 targets: Mdm2 protein, p21waf1 mRNA and protein, and the cyclin G promoter. Despite marked induction of p21waf1, cells with active p53 failed to undergo growth arrest, which is probably due to the presence of a non-functional retinoblastoma protein (pRb) in these cells. Apoptosis also was not observed, even after prolonged (48 h) serum starvation or exposure to cisplatinum. Lack of apoptosis was correlated with unchanged bax mRNA levels following p53 induction. Additionally, albumin mRNA levels remained unchanged, and there was no change in basal transactivation of a reporter containing the promoter of the haptoglobin gene, encoding an acute phase protein. This suggests that growth arrest may be required to promote liver-specific gene expression. Overall, our data demonstrate that introduction of transcriptionally active p53 does not alter the malignant, dedifferentiated phenotype of Hep 3B hepatoma cells. Hence, not all cancer cells are equally responsive to the re-activation of wild-type 53. The ability of a cancer cell to undergo p53-mediated phenotypic alterations may depend on the retention of functional downstream effector pathways.
Similar articles
- Involvement of p53, nuclear factor kappaB and Fas/Fas ligand in induction of apoptosis and cell cycle arrest by saikosaponin d in human hepatoma cell lines.
Hsu YL, Kuo PL, Chiang LC, Lin CC. Hsu YL, et al. Cancer Lett. 2004 Sep 30;213(2):213-21. doi: 10.1016/j.canlet.2004.03.044. Cancer Lett. 2004. PMID: 15327837 - p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells.
Kagawa S, Fujiwara T, Hizuta A, Yasuda T, Zhang WW, Roth JA, Tanaka N. Kagawa S, et al. Oncogene. 1997 Oct 16;15(16):1903-9. doi: 10.1038/sj.onc.1201362. Oncogene. 1997. PMID: 9365236 - Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
Kaneuchi M, Yamashita T, Shindoh M, Segawa K, Takahashi S, Furuta I, Fujimoto S, Fujinaga K. Kaneuchi M, et al. Mol Carcinog. 1999 Sep;26(1):44-52. Mol Carcinog. 1999. PMID: 10487521 - Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways.
Liebermann DA, Hoffman B, Steinman RA. Liebermann DA, et al. Oncogene. 1995 Jul 6;11(1):199-210. Oncogene. 1995. PMID: 7624128 Review.
Cited by
- Nucleoporin Nup155 is part of the p53 network in liver cancer.
Holzer K, Ori A, Cooke A, Dauch D, Drucker E, Riemenschneider P, Andres-Pons A, DiGuilio AL, Mackmull MT, Baßler J, Roessler S, Breuhahn K, Zender L, Glavy JS, Dombrowski F, Hurt E, Schirmacher P, Beck M, Singer S. Holzer K, et al. Nat Commun. 2019 May 14;10(1):2147. doi: 10.1038/s41467-019-10133-z. Nat Commun. 2019. PMID: 31089132 Free PMC article. - Sustained-Release and pH-Adjusted Alginate Microspheres-Encapsulated Doxorubicin Inhibit the Viabilities in Hepatocellular Carcinoma-Derived Cells.
Pan CT, Yu RS, Yang CJ, Chen LR, Wen ZH, Chen NY, Ou HY, Yu CY, Shiue YL. Pan CT, et al. Pharmaceutics. 2021 Sep 7;13(9):1417. doi: 10.3390/pharmaceutics13091417. Pharmaceutics. 2021. PMID: 34575492 Free PMC article. - Cholesterol-Lowering Phytochemicals: Targeting the Mevalonate Pathway for Anticancer Interventions.
Laka K, Makgoo L, Mbita Z. Laka K, et al. Front Genet. 2022 Mar 22;13:841639. doi: 10.3389/fgene.2022.841639. eCollection 2022. Front Genet. 2022. PMID: 35391801 Free PMC article. Review. - Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.
Zhang H, Wang H, Zhang J, Qian G, Niu B, Fan X, Lu J, Hoffman AR, Hu JF, Ge S. Zhang H, et al. Mol Ther. 2009 Jan;17(1):57-64. doi: 10.1038/mt.2008.236. Epub 2008 Nov 18. Mol Ther. 2009. PMID: 19018252 Free PMC article. - Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells.
Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, Verfaillie CM. Schwartz RE, et al. J Clin Invest. 2002 May;109(10):1291-302. doi: 10.1172/JCI15182. J Clin Invest. 2002. PMID: 12021244 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous